DE-THE-LYCRA-COMPANY
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that it is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. The LYCRA Company Pavilion in Hall 4.1 (Booth E56) features 931 square meters of exhibit space and 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827097449/en/
The LYCRA Company is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. Its pavilion in Hall 4.1 (Booth E56) features 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.” Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how bio-derived LYCRA® fiber made with QIRA® can help accelerate decarbonization in the fashion industry. (Photo: Business Wire)
The LYCRA Company will highlight products designed to meet consumer needs and help reduce the environmental impact of apparel products:
- Bio-derived LYCRA® fiber made with QIRA®, the industry’s first renewable spandex available at scale, will launch in the first half of 2025. Made from annually grown field corn, it's expected to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* while delivering equivalent performance to the original fiber. Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how this patented innovation can help accelerate decarbonization in the fashion industry.
- LYCRA® FiT400™ fiber is a unique bicomponent fiber engineered to optimize the comfort and performance of knits while delivering a durable, soft hand feel, all-day stretch, long-lasting fit, and cooling comfort. This Global Recycled Standard-certified fiber contains 60% recycled PET and 14.4% bio-derived resources.
- COOLMAX® EcoMade fiber made from 100% textile waste delivers cool and dry comfort to various garment types, while THERMOLITE® EcoMade fiber made from 100% textile waste adds lightweight warmth.
“We are thrilled to showcase our sustainable solutions at Intertextile that will help our customers reduce their carbon footprint and support their sustainability goals,” said Jason Wang, vice president, Asia. “We look forward to helping attendees find the consumer-driven, market-relevant branded solutions they need to take their business to the next level.”
The LYCRA Company will also showcase LYCRA® ADAPTIV fiber, one of the company’s fastest-growing products. Brands and retailers worldwide appreciate how it enables inclusive sizing and delivers a second-skin fit, enhanced comfort in motion, and greater functionality to activewear, intimate apparel, denim, and more. Regina Miracle, a leading garment maker and a key value chain partner of The LYCRA Company, will exhibit garment samples.
The booth will also feature garment samples of new LYCRA FitSense® denim technology, a targeted shaping innovation for stretch denim to deliver a customizable fit to different body types and shapes, a breakthrough for the industry launched this year. Through a combination of fiber, fabric, and garment processing technologies, this discreet and invisible solution retains the authentic denim look and feel that consumers desire.
To learn more about The LYCRA Company’s latest innovations and commitment to a more sustainable future, visit Intertextile Booth E56 in Hall 4.1 and Booth A36 in Hall 5.1, or visit this website.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA® FiT400™, LYCRA FitSense®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827097449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom